Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Formation and toxicity of soluble polyglutamine oligomers in living cells.

Lajoie P, Snapp EL.

PLoS One. 2010 Dec 28;5(12):e15245. doi: 10.1371/journal.pone.0015245.

2.

An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1.

Prudencio M, Durazo A, Whitelegge JP, Borchelt DR.

Hum Mol Genet. 2010 Dec 15;19(24):4774-89. doi: 10.1093/hmg/ddq408. Epub 2010 Sep 24.

3.

Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle.

Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, Ng C, Glabe C, Thompson LM, Muchowski PJ.

J Biol Chem. 2010 Dec 3;285(49):38183-93. doi: 10.1074/jbc.M110.160218. Epub 2010 Sep 23.

4.

Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.

Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S.

J Neurosci. 2010 Aug 4;30(31):10541-50. doi: 10.1523/JNEUROSCI.0146-10.2010.

5.

A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis.

Ossato G, Digman MA, Aiken C, Lukacsovich T, Marsh JL, Gratton E.

Biophys J. 2010 Jun 16;98(12):3078-85. doi: 10.1016/j.bpj.2010.02.058.

6.

Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool.

Olshina MA, Angley LM, Ramdzan YM, Tang J, Bailey MF, Hill AF, Hatters DM.

J Biol Chem. 2010 Jul 9;285(28):21807-16. doi: 10.1074/jbc.M109.084434. Epub 2010 May 5.

7.

Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.

Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, DiFiglia M, Thompson LM, Muchowski PJ.

J Biol Chem. 2010 May 7;285(19):14777-90. doi: 10.1074/jbc.M109.093708. Epub 2010 Mar 10.

8.

Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP.

Hum Mol Genet. 2010 Jan 1;19(1):65-78. doi: 10.1093/hmg/ddp467.

9.

Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease.

Prudencio M, Hart PJ, Borchelt DR, Andersen PM.

Hum Mol Genet. 2009 Sep 1;18(17):3217-26. doi: 10.1093/hmg/ddp260. Epub 2009 May 30.

10.

Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS.

Karch CM, Prudencio M, Winkler DD, Hart PJ, Borchelt DR.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7774-9. doi: 10.1073/pnas.0902505106. Epub 2009 Apr 30.

11.

Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants.

Banci L, Bertini I, Boca M, Calderone V, Cantini F, Girotto S, Vieru M.

Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6980-5. doi: 10.1073/pnas.0809845106. Epub 2009 Apr 14.

12.

Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism.

Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, Byeon IJ, Anjum DH, Kodali R, Creamer TP, Conway JF, Gronenborn AM, Wetzel R.

Nat Struct Mol Biol. 2009 Apr;16(4):380-9. doi: 10.1038/nsmb.1570. Epub 2009 Mar 8.

13.

Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse.

Wang L, Deng HX, Grisotti G, Zhai H, Siddique T, Roos RP.

Hum Mol Genet. 2009 May 1;18(9):1642-51. doi: 10.1093/hmg/ddp085. Epub 2009 Feb 19.

14.

Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS.

Wang J, Farr GW, Zeiss CJ, Rodriguez-Gil DJ, Wilson JH, Furtak K, Rutkowski DT, Kaufman RJ, Ruse CI, Yates JR 3rd, Perrin S, Feany MB, Horwich AL.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1392-7. doi: 10.1073/pnas.0813045106. Epub 2009 Jan 26.

15.

Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates.

Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR.

Nat Cell Biol. 2009 Feb;11(2):219-25. doi: 10.1038/ncb1830. Epub 2009 Jan 18.

16.

Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.

Wang Q, Johnson JL, Agar NY, Agar JN.

PLoS Biol. 2008 Jul 29;6(7):e170. doi: 10.1371/journal.pbio.0060170.

17.

SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization.

Banci L, Bertini I, Boca M, Girotto S, Martinelli M, Valentine JS, Vieru M.

PLoS One. 2008 Feb 27;3(2):e1677. doi: 10.1371/journal.pone.0001677.

18.

Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.

Takahashi T, Kikuchi S, Katada S, Nagai Y, Nishizawa M, Onodera O.

Hum Mol Genet. 2008 Feb 1;17(3):345-56. Epub 2007 Oct 18.

PMID:
17947294
19.

Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS.

Banci L, Bertini I, Durazo A, Girotto S, Gralla EB, Martinelli M, Valentine JS, Vieru M, Whitelegge JP.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11263-7. Epub 2007 Jun 25.

20.

Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy.

Takahashi Y, Okamoto Y, Popiel HA, Fujikake N, Toda T, Kinjo M, Nagai Y.

J Biol Chem. 2007 Aug 17;282(33):24039-48. Epub 2007 Jun 15.

Supplemental Content

Support Center